SUSAN DUBOSE: Open Payments
NPI 1619274032 · SUMRALL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$739 in 39 payments from 10 companies in 2025. Trend: 2023 $467 · 2024 $880 · 2025 $739
Food & beverage: $739
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $250 |
| AstraZeneca Pharmaceuticals LP | 6 | $115 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $88 |
| Exact Sciences Corporation | 3 | $64 |
| Novo Nordisk Inc | 3 | $55 |
| Amgen Inc. | 3 | $55 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $35 |
| Tris Pharma Inc | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $13 |
Products named: VRAYLAR, XIFAXAN, FARXIGA, QULIPTA, EVENITY, The Cologuard Plus Collection Kit, UBRELVY, Kerendia.
Industry payments across MS — which companies pay providers there.
